pehub.com -- Bellicum Pharmaceuticals Inc., a Houston-based drug startup focused on prostate cancer, has raised $4.5 million in Series A and convertible note financing. The company has now raised a total of $8.5 million, including $1.45 million from the Texas Emerging Technology Fund.
